# A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

> **NCT04063163** · PHASE3 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 585 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** HLX10
- **DRUG:** carboplatin and etoposide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04063163
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-12
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 585 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04063163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04063163, "A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT04063163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*